BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Maruishi Pharmaceutical Co.\, Ltd. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Maruishi Pharmaceutical Co.\, Ltd
 .'s drugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06593392-883@assetmemo.bio
DTSTAMP:20261121T005948Z
DTSTART;VALUE=DATE:20290815
DTEND;VALUE=DATE:20290816
SUMMARY:Korsuva (Difelikefalin): Phase 2 readout est. (NCT06593392)
DESCRIPTION:Korsuva (Difelikefalin)\, phase 2\, Chronic Kidney Disease.\nSt
 udy: Safety and Tolerability of Difelikefalin in Adolescents on Haemodialy
 sis With Moderate-to-Severe Pruritus\nEstimated primary completion: 15 Aug
 ust 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/difelikefal
 in#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6593392
URL:https://assetmemo.bio/drug/difelikefalin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
